SCHEMBL2211394

SCHEMBL2211394

COc1ccc(CN(CCP(=O)(C(C)C)C(C)C)C(=O)O)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.48
▸ USP2 O75604 1/20 0.48
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ TDP1 Q9NUW8 3/20 0.46
▸ ALDH1A1 P00352 6/20 0.44
▸ NPSR1 Q6W5P4 2/20 0.44
▸ HTT P42858 2/20 0.44
▸ L3MBTL1 Q9Y468 2/20 0.44
▸ ALOX12 P18054 1/20 0.44
▸ GPR55 Q9Y2T6 1/20 0.44
▸ LDHA P00338 1/20 0.44
▸ LPAR1 Q92633 2/20 0.44
▸ LPAR5 Q9H1C0 2/20 0.44
▸ ACHE P22303 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ PTGES O14684 1/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2209882 0.85 TSHR (0.40) TSHRUSP2MEN1KMT2ATDP1
SCHEMBL3484433 0.79 TDP1 (0.60) TSHRUSP2MEN1KMT2ATDP1
SCHEMBL3614141 0.78 TDP1 (0.54) TSHRUSP2MEN1KMT2ATDP1
SCHEMBL18646559 0.77 TSHR (0.62) TSHRUSP2MEN1KMT2ATDP1
SCHEMBL20472046 0.76 ALDH1A1 (0.52) TSHRUSP2MEN1KMT2ATDP1
SCHEMBL2209885 0.74 MEN1 (0.40) TSHRMEN1KMT2AALDH1A1NPSR1
SCHEMBL25828611 0.73 TSPO (0.50) TSHRUSP2MEN1KMT2ATDP1
SCHEMBL26025186 0.73 ALDH1A1 (0.52) TSHRUSP2MEN1KMT2ATDP1
SCHEMBL6121816 0.73 TSHR (0.73) TSHRUSP2MEN1KMT2ATDP1
SCHEMBL25132132 0.72 TSHR (0.53) TSHRUSP2MEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7981874-B2 Phosphorus derivatives as histone deacetylase inhibitors MERCK SHARP & DOHME CORP. (US) 2011-07-19 — — US disclosed
US-20090270351-A1 PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS MERCK SHARP & DOHME CORP. 2009-10-29 — — US disclosed
EP-2049124-A2 PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS Merck & Co., Inc. (US) 2009-04-22 — — EP disclosed
WO-2008010985-A2 PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS MERCK & CO., INC. (US) 2008-01-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270351-A1 PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS HDAC5, PPM1A, PTEN TSHR 1176/4885USP2 2046/4885MEN1 2398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback